Table 1.
Baseline characteristics of study population according to groups eligibility criteria.
| Total | SGLT2-i users | Non-SGLT2-i users | P -value | |
|---|---|---|---|---|
| (N = 646) | (N = 111) | (N = 535) | ||
| Age, median (IQR) | 70 (61–79) | 66 (59–73) | 72 (62–80) | <0.001 |
| Male Sex, n (%) | 498 (77.1) | 90 (81.1) | 405 (75.7) | 0.222 |
| BMI | 27.7 (25–31.3) | 27.1 (24.6–30) | 27.7 (25–31.4) | 0.245 |
| Smoking, n (%) | 370 (57.3) | 67 (60.4) | 303 (56.6) | 0.470 |
| Hypertension, n (%) | 541 (83.7) | 98 (88.3) | 443 (82.8) | 0.154 |
| Dyslipidemia, n (%) | 508 (78.6) | 90 (81.1) | 418 (78.1) | 0.490 |
| PAD, n (%) | 82 (12.7) | 16 (14.4) | 66 (12.3) | 0.550 |
| COPD, n (%) | 90 (13.9) | 15 (13.5) | 75 (14) | 0.889 |
| CKD, n (%) | 58 (9) | 10 (9) | 47 (8.8) | 0.886 |
| Previous TIA/CVA, n (%) | 52 (8) | 10 (9) | 42 (7.9) | 0.683 |
| Previous AMI, n (%) | 169 (26.2) | 30 (27) | 136 (25.4) | 0.724 |
| Previous PCI, n (%) | 183 (28.3) | 35 (31.5) | 144 (26.9) | 0.322 |
| Antiplatelets, n (%) | 321 (49.7) | 60 (54.1) | 261 (48.8) | 0.312 |
| Anticoagulation, n (%) | 55 (8.5) | 6 (5.4) | 49 (9.2) | 0.197 |
| RAAS, n (%) | 378 (58.5) | 69 (62.2) | 309 (57.8) | 0.391 |
| Diuretics, n (%) | 196 (30.3) | 31 (27.9) | 165 (30.8) | 0.543 |
| B-blockers, n (%) | 296 (45.8) | 55 (49.5) | 241 (45) | 0.386 |
| CCB, n (%) | 197 (30.5) | 35 (31.5) | 162 (30.3) | 0.794 |
| Statins, n (%) | 329 (50.9) | 61 (55) | 268 (50.1) | 0.351 |
| Low/moderate intensity | 238 (72.3) | 39 (63.9) | 199 (74.3) | 0.104 |
| High intensity | 91 (27.7) | 22 (36.1) | 69 (25.7) | |
| Ezetimibe, n (%) | 78 (12.1) | 15 (13.5) | 63 (11.8) | 0.609 |
| Metformin, n (%) | 467 (72.3) | 80 (72.1) | 387 (72.3) | 0.955 |
| Sulfonylureas, n (%) | 166 (25.7) | 13 (11.7) | 153 (28.6) | 0.001 |
| DPP-4 Inhibitors, n (%) | 54 (8.4) | 8 (7.2) | 46 (8.6) | 0.630 |
| GLP-1 Agonist, n (%) | 19 (2.9) | 5 (4.5) | 14 (2.6) | 0.284 |
Continuous variables are presented as mean ± SD or as median (IQR); categorical variables as number (%). AMI, acute myocardial infarction; BB, B-blockers; BMI, Body Mass Index; CCB, Calcium Channel Blockers; CKD, chronic kidney disease with 30 < GFR < 60 ml/min; COPD, chronic obstructive pulmonary disease; CVA, cerebrovascular accident; DPP-4, Dipeptidyl peptidase 4; GLP-1, Glucagon-like peptide-1; PAD, peripheral artery disease; PCI, Percutaneous Coronary Intervention; RAAS: renin-angiotensin-aldosterone system; TIA, transient ischaemic attack.